



COMMENT ON EDELMAN AND POLONSKY

Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control.

Diabetes Care 2017;40:1425–1432

Diabetes Care 2018;41:e17 | <https://doi.org/10.2337/dc17-1826>

Dario Giugliano,¹
 Maria Ida Maiorino,²
 Giuseppe Bellastella,¹ and
 Katherine Esposito²

Edelman and Polonsky (1) suggest that poor adherence to pharmacotherapy is largely (~75%) responsible for the gap between clinical efficacy from randomized controlled trials and real-world effectiveness of antihyperglycemic drugs. As no single strategy can be applied successfully to all patients with type 2 diabetes in order to improve medication adherence, other approaches are suggested, including innovation in delivery methods and reduction of the number of daily pills, shared strategies between clinicians and patients, and easier access to medications.

Only 11 years ago, the first newer diabetes drug (sitagliptin) was considered innovative for the time (once-daily administration, lower risk of hypoglycemia, and similar HbA_{1c} reduction compared with older drugs). Moreover, the consolidated suggestion by the American Diabetes Association (ADA) to approach diabetes therapy on a personalized basis remains apparently unsuccessful, given that the proportion of patients with diabetes who achieve an HbA_{1c} target of <7% (<53 mmol/mol) is still around 50%, with no appreciable change over the last decade. Finally, facilitated access to diabetes medications must await the time needed for newer diabetes drugs to become generic, as the global sales for

antidiabetes drugs will be \$95–110 billion in 2021 (2).

We suspect that poor adherence to pharmacotherapy is also linked to a more generalized clinical (therapeutic) inertia of clinicians (3), who may be dissatisfied about some dissonance among therapeutic guidelines released by scientific associations. Take, for example, the reputed scientific guidelines about diabetes treatment released by the ADA, the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE), and the American College of Physicians (ACP) in 2017. For ADA (4), the choice of the second drug after metformin failure should be made after careful consideration of many factors, including efficacy, adverse effects (hypoglycemia and weight change), and cost; for AACE and ACE (5), there is a hierarchy of choices after metformin failure, with preference given to newer drugs (glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors); for ACP (6), the evidence is weak for recommending any particular oral drug to add to metformin, and clinicians and patients must be allied to select among medications after discussing benefits, adverse effects, and costs. This may generate a sense of frustration among clinicians, who may perceive that the

choice of a second drug after metformin failure has marginal importance, especially in light of the residual vascular risk that remains high after intensive glycemic control.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

1. Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. *Diabetes Care* 2017;40:1425–1432
2. QuintilesIMS Institute. Outlook for global medicines through 2021 [Internet], 2016. Available from http://static.correofarmaceutico.com/docs/2016/12/12/qihi_outlook_for_global_medicines_through_2021.pdf. Accessed 31 August 2017
3. Giugliano D, Esposito K. Clinical inertia as a clinical safeguard. *JAMA* 2011;305:1591–1592
4. American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec. 8. In *Standards of Medical Care in Diabetes—2017*. *Diabetes Care* 2017;40(Suppl. 1):S64–S74
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. *Endocr Pract* 2017;23:207–238
6. Qaseem A, Barry MJ, Humphrey LL, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. *Ann Intern Med* 2017;166:279–290

¹Division of Endocrinology and Metabolic Diseases, Department of Medical, Surgical, Neurological, Metabolic Sciences and Aging, University of Campania “Luigi Vanvitelli,” Naples, Italy

²Diabetes Unit, Department of Medical, Surgical, Neurological, Metabolic Sciences and Aging, University of Campania “Luigi Vanvitelli,” Naples, Italy
 Corresponding author: Dario Giugliano, dario.giugliano@unicampania.it.

© 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.